drugset / Trial / NCT01118598

Effect of Nicotinic Acid on Cardiovascular Risks Indices in Polycystic Ovary Syndrome

NCT01118598

RandomizedParallel-groupDouble-blindTreatment

Summary

Niacin will improve postprandial hyperlipidaemia and cardiovascular risks indices via its lipid lowering as well as via pleiotropic effects in patients with polycystic ovary syndrome (PCOS).

Timeline

Start
2010-06
Primary completion
2012-05
Completion
2012-05

Drugs

EvaluationDrugModalityDoseRoute
Comparator Niacin Small molecule 2000 mg
Comparator laropiprant Small molecule 40 mg